Fadi Haddad

Also affiliated with The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia”.

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2024)10.1182/bloodadvances.2023012231

N/A

0.940DataRank · unranked

34 citations

Elias Jabbour, Nitin Jain, Jayastu Senapati, Lewis Nasr, Fadi Haddad +18 more

Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial

The Lancet Haematology(2024)10.1016/s2352-3026(24)00250-3

N/A

0.561DataRank · unranked

17 citations

Daniel Nguyen, Elias Jabbour, Jayastu Senapati, Zhihong Zeng, Ghayas C. Issa +14 more

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab

Journal of Hematology & Oncology(2025)10.1186/s13045-025-01709-y

N/A

0.471DataRank · unranked

17 citations

Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, Omer Karrar +8 more

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Cancer(2025)10.1002/cncr.35840

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour +13 more

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Advances(2023)10.1182/bloodadvances.2022009391

N/A

0DataRank · unranked

29 citations

Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang +22 more

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

American Journal of Hematology(2023)10.1002/ajh.27037

N/A

0DataRank · unranked

20 citations

Koji Sasaki, Aram Bidikian, Ghayas C. Issa, Tapan M. Kadia, Nitin Jain +11 more

Association between bariatric surgery and outcomes in chronic myeloid leukemia

Cancer(2023)10.1002/cncr.34725

N/A

0DataRank · unranked

11 citations

Hagop M. Kantarjian, Aram Bidikian, Elias Jabbour, Nicholas J. Short, Jing Ning +10 more

Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.11.003

N/A

0DataRank · unranked

4 citations

Koji Sasaki, Jayastu Senapati, Shimin Hu, Sara Dellasala, Ghayas C. Issa +3 more

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Blood(2024)10.1182/blood-2024-211599

N/A

0DataRank · unranked

3 citations

H. Kantarjian, Edward Ayoub, Akhil Jain, Tapan M. Kadia, Courtney D. DiNardo +13 more

Management of chronic myeloid leukemia in 2025

Cancer(2025)10.1002/cncr.35953

N/A

0DataRank · unranked

37 citations

Massimo Breccia, Fadi Haddad, Rüdiger Hehlmann, Ghayas C. Issa, Hemant Malhotra +5 more

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016565

N/A

0DataRank · unranked

3 citations

Hagop M. Kantarjian, Nitin B. Jain, Tapan M. Kadia, Jayastu Senapati, Fadi Haddad +12 more

Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18)

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.03.010

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Álex Bataller, Koji Sasaki, Guilin Tang, Sanam Loghavi +7 more

SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated with Chemotherapy-Free Regimens without Transplant

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.06.019

N/A

0DataRank · unranked

0 citations

Hagop M. Kantarjian, Jayastu Senapati, Nitin Jain, Nicholas J. Short, Elias Jabbour +1 more

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

Blood Cancer Journal(2021)10.1038/s41408-021-00557-6

N/A

0DataRank · unranked

99 citations

Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning +16 more

SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia—How to Define the Treatment Value?

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.10.001

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Massimo Breccia, Rüdiger Hehlmann, Hemant Malhotra, Franck E. Nicolini +3 more

Contemporary outcomes for adults with AML requiring ICU admission.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7025

N/A

0DataRank · unranked

4 citations

Koji Sasaki, Alexis Geppner, Fadi Haddad, Shehab Mohamed, Daniel Rivera +15 more

Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019

Cancer(2023)10.1002/cncr.35038

N/A

0DataRank · unranked

32 citations

Fadi Haddad, Nicholas J. Short, Nitin Jain, Ghayas C. Issa, Elias Jabbour +2 more

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.12.016

N/A

0DataRank · unranked

23 citations

Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall +11 more